Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
09:40am, Friday, 28'th Jun 2024
Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
10:10am, Monday, 24'th Jun 2024
Denali Therapeutics (DNLI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the ne
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
12:36pm, Thursday, 06'th Jun 2024
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
02:21pm, Tuesday, 04'th Jun 2024
Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro
Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
12:30pm, Monday, 13'th May 2024
Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks w
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
09:21am, Wednesday, 08'th May 2024
Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
04:01pm, Tuesday, 07'th May 2024
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cros
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cros
Why Denali Therapeutics (DNLI) Stock Might be a Great Pick
09:51am, Tuesday, 09'th Apr 2024
Denali Therapeutics (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
12:36pm, Thursday, 28'th Mar 2024
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
To the Moon and Beyond: 7 Stocks With Cosmic Potential
04:30pm, Thursday, 14'th Mar 2024
Stocks with moonshot potential are drawing attention amidst the current bullishness in the stock market. Despite the latest inflation reports pointing to a potential delay in the Federal Reserve's int
Denali: Leveraging Transport Vehicle Technology For Neurological Gains
10:05pm, Wednesday, 06'th Mar 2024
Denali's stock performance has been flat despite the biotech sector's 20% rise; recently raised $500 million in a PIPE. ALS trial failure with partner Sanofi pressured stock; Denali's focus is on tran
Top 3 Wall Street stock picks for March
08:51am, Wednesday, 06'th Mar 2024
While the stock market is not yet free of recessionary fears and remains affected by high interest rates, 2024 has, so far, brought significant positive developments if things are to be judged by majo
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
09:11am, Wednesday, 28'th Feb 2024
Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.
